Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Research & Development (2020 - 2025)

Roivant Sciences' Research & Development history spans 6 years, with the latest figure at $165.4 million for Q4 2025.

  • For Q4 2025, Research & Development rose 16.8% year-over-year to $165.4 million; the TTM value through Dec 2025 reached $624.5 million, up 21.65%, while the annual FY2025 figure was $550.4 million, 25.12% up from the prior year.
  • Research & Development reached $165.4 million in Q4 2025 per ROIV's latest filing, roughly flat from $164.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $165.4 million in Q4 2025 to a low of $78.5 million in Q2 2021.
  • Average Research & Development over 5 years is $131.8 million, with a median of $132.1 million recorded in 2021.
  • Peak YoY movement for Research & Development: plummeted 32.1% in 2021, then soared 73.0% in 2022.
  • A 5-year view of Research & Development shows it stood at $137.3 million in 2021, then dropped by 8.6% to $125.5 million in 2022, then dropped by 13.85% to $108.1 million in 2023, then soared by 30.93% to $141.6 million in 2024, then grew by 16.8% to $165.4 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Research & Development are $165.4 million (Q4 2025), $164.6 million (Q3 2025), and $152.9 million (Q2 2025).